Flucytosine therapeutic monitoring: 15 years experience from the UK

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 791-793

  Pasqualotto, A C ^a   Howard, S J ^a   Moore, C B ^a   Denning, D W ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Bioassay; Candida; Cryptococcus; Drug monitoring

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BIOASSAY; CANDIDA GLABRATA; CHILD; CHILD DEVELOPMENT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; EXPERIENCE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; UNITED KINGDOM; URINARY TRACT; BACTERICIDAL ACTIVITY; BLOOD; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL ASSAY; DRUG MONITORING; FLUCYTOSINE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; SERUM BACTERICIDAL TEST;

EID: 34249992660     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl550     Document Type: Article

References (10)

1. Saag MS, Graybill RJ, Larsen RA et al Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30 710-8.
2. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet 1991; 337: 1577-80.
3. Working Group of the British Society for Mycopathology. Laboratory methods for flucylosine (5-fluorocytosine). J Antimicrob Chemother 1984; 14: 1-8.
4. Soltani M, Tobin CM, Bowker KE et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: A 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006; 28: 574-7.
5. Normark S, Schonebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother 1972; 2: 114-21.
6. Stamm AM, Diasio RB, Dismukes WE et al. Toxicity of amphotericin B plus flucylosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83: 236-42.
7. Petersen D, Demertzis S, Freund M et al. Individualization of 5-fluorocytosine therapy. Chemotherapy 1994; 40: 149-56.
8. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
9. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Appioved Standard M27-A. NCCLS, Villanova, PA, USA, 1997.
10. Hope WW, Wam PA, Sharp A et al. The derivation of an in vivo drug-exposure breakpoint for flucytosine against Candida albicans and the impact of the minimum inhibitory concentration, growth rate and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 2006; 50: 3680-8.